Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMC-309 (anti-VISTA) with or without pembrolizumab in advanced solid tumors
NCT05957081Phase 1Recruiting
- Sponsor
- PharmAbcine
- Start
- Jan 2024
- Primary completion
- Oct 2029
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PMC-309 in Solid tumors (4 arms), sponsored by PharmAbcine. Primary endpoints: Abnormal Vital Signs, Abnormal Physical Examination and 6 more. Started Jan 2024; status: recruiting.
02
Drugs
PMC-309
03
Conditions
Solid tumors
Beyond the preview
Go deeper on NCT05957081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957081.